Brief: Atara Bio Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel

Atara Biotherapeutics

17/07/2024 14:13

July 17 (Reuters) - Atara Biotherapeutics Inc  ATRA.O :
    * ATARA BIOTHERAPEUTICS ANNOUNCES U.S. FDA ACCEPTANCE AND
PRIORITY
REVIEW OF THE BIOLOGICS LICENSE APPLICATION FOR TABELECLEUCEL
(TAB-CEL®) FOR THE TREATMENT OF EPSTEIN-BARR VIRUS POSITIVE
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE
    * ATARA BIOTHERAPEUTICS INC -PRESCRIPTION DRUG USER FEE ACT
(PDUFA) TARGET ACTION DATE OF JANUARY 15, 2025
    * ATARA BIOTHERAPEUTICS INC - BLA ACCEPTANCE TRIGGERS $20
MILLION
MILESTONE PAYMENT FROM PIERRE FABRE LABORATORIES
    * ATARA BIOTHERAPEUTICS INC - $20M MILESTONE PAYMENT
TRIGGERED BY
BLA ACCEPTANCE
    * ATARA BIOTHERAPEUTICS- BLA ACCEPTANCE TRIGGERS $20 MILLION
MILESTONE PAYMENT WITH ADDITIONAL $60 MILLION MILESTONE IF
APPROVED BY FDA

Source text for Eikon:  ID:nBw9sGqw9a 
Further company coverage:  ATRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))